The effect of guselkumab on inhibiting radiographic progression in patients with active psoriatic arthritis: study protocol for APEX, a Phase 3b, multicenter, randomized, double-bl... by Ritchlin, CT, Coates, LC, Mease, PJ, van der Heijde, D, Song, J, Jiang, Y, Shawi, M, Kollmeier, AP, Rahman, P

Continuous improvement through differential trajectories of individual minimal disease activity criteria with guselkumab in active psoriatic arthritis: post hoc analysis of a phase... by Coates, LC, Rahman, P, Mease, PJ, Shawi, M, Rampakakis, E, Kollmeier, AP, Xu, XL, Chakravarty, SD, McInnes, IB, Tam, L-S

Efficacy and safety of guselkumab in patients with active psoriatic arthritis who are inadequate responders to tumour necrosis factor inhibitors: results through one year of a phas... by Coates, L, Gossec, L, Theander, E, Bergmans, P, Neuhold, M, Karyekar, CS, Shawi, M, Noel, W, Schett, G, McInnes, IB

Guselkumab provides durable improvement across psoriatic arthritis disease domains: post hoc analysis of a phase 3, randomised, double-blind, placebo-controlled study by Coates, LC, Gossec, L, Zimmermann, M, Shawi, M, Rampakakis, E, Shiff, NJ, Kollmeier, AP, Xu, XL, Nash, P, Mease, PJ, Helliwell, PS

Guselkumab provides sustained domain-specific and comprehensive efficacy using composite indices in patients with active psoriatic arthritis by Coates, L, Ritchlin, CT, Gossec, L, Helliwell, PS, Rahman, P, Kollmeier, AP, Xu, XL, Shawi, M, Karyekar, CS, Contré, C, Noël, W, Sheng, S, Wang, Y, Xu, S, Mease, PJ

Safety of guselkumab with and without prior TNF-α inhibitor treatment: pooled results across four studies in patients with psoriatic arthritis by Rahman, P, Boehncke, W-H, Mease, PJ, Gottlieb, AB, McInnes, IB, Shawi, M, Wang, Y, Sheng, S, Kollmeier, AP, Theander, E, Yu, J, Leibowitz, E, Marrache, AM, Coates, LC

Guselkumab provides sustained domain-specific and comprehensive efficacy as assessed using composite endpoints in patients with active psoriatic arthritis free by Coates, LC, Ritchlin, CT, Gossec, L, Helliwell, P, Rahman, P, Hsia, EC, Kollmeier, A, Xu, XL, Karyekar, C, Shawi, M, Noel, W, Jiang, Y, Sheng, S, Wang, Y, Mease, PJ

Modulation of interleukin-23 signaling with guselkumab in biologic-naive patients versus tumor necrosis factor inhibitor–inadequate responders with active psoriatic arthritis by Siebert, S, Coates, LC, Schett, G, Raychaudhuri, SP, Chen, W, Gao, S, Seridi, L, Chakravarty, SD, Shawi, M, Lavie, F, Sharaf, M, Zimmermann, M, Kollmeier, AP, Xu, XL, Rahman, P, Mease, PJ, Deodhar, A

Modulation of Interleukin‐23 Signaling With Guselkumab in Biologic‐Naive Patients Versus Tumor Necrosis Factor Inhibitor–Inadequate Responders With Active Psoriatic Arthritis by Siebert, S, Coates, LC, Schett, G, Raychaudhuri, SP, Chen, W, Gao, S, Seridi, L, Chakravarty, SD, Shawi, M, Lavie, F, Sharaf, M, Zimmermann, M, Kollmeier, AP, Xu, XL, Rahman, P, Mease, PJ, Deodhar, A